Literature DB >> 16971390

Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis.

Yuan-Li Zhang1, Antonio Hernandez-Ono, Patty Siri, Stuart Weisberg, Donna Conlon, Mark J Graham, Rosanne M Crooke, Li-Shin Huang, Henry N Ginsberg.   

Abstract

Insulin-resistant apoB/BATless mice have hypertriglyceridemia because of increased assembly and secretion of very low density apolipoprotein B (apoB) and triglycerides compared with mice expressing only apoB (Siri, P., Candela, N., Ko, C., Zhang, Y., Eusufzai, S., Ginsberg, H. N., and Huang, L. S. (2001) J. Biol. Chem. 276, 46064-46072). Despite increased very low density lipoprotein secretion, apoB/BATless mice have fatty livers. We found that hepatic mRNA levels of key lipogenic enzymes, acetyl-CoA carboxylase, fatty-acid synthase, and stearoyl-CoA desaturase-1 were increased in apoB/BATless mice compared with levels in apoB mice, suggesting increased lipogenesis in apoB/BATless mice. This was confirmed by determining incorporation of tritiated water into fatty acids. Neither the hepatic mRNA of the lipogenic transcription factor, SREBP-1c (sterol-response element-binding protein 1c), nor the nuclear levels of the mature form of SREBP-1 protein were elevated in apoB/BATless mice. By contrast, hepatic levels of peroxisomal proliferator-activated receptor 2 (PPARgamma2) mRNA and protein were specifically increased in apoB/BATless mice, as were hepatic mRNA levels of two targets of PPARgamma, CD36 and aP2. Treatment of apoB/BATless mice for 4 weeks with intraperitoneal injections of a PPARgamma antisense oligonucleotide resulted in dramatic reductions of both PPARgamma1 and PPARgamma2 mRNA, PPARgamma2 protein, and mRNA levels of fatty-acid synthase and acetyl-CoA carboxylase. These changes were associated with decreased hepatic de novo lipogenesis and hepatic triglyceride concentrations. We conclude that hepatic steatosis in apoB/BATless mice is associated with elevated rates of hepatic lipogenesis that are linked directly to increased hepatic expression of PPARgamma2. The mechanism whereby hepatic Ppargamma2 gene expression is increased and how PPARgamma2 stimulates lipogenesis is under investigation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16971390     DOI: 10.1074/jbc.M604709200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  61 in total

1.  Prosteatotic genes are associated with unsaturated fat suppression of saturated fat-induced hepatic steatosis in C57BL/6 mice.

Authors:  Tuoyu Geng; Lili Xia; Sarah Russo; Davida Kamara; Lauren Ashley Cowart
Journal:  Nutr Res       Date:  2015-07-02       Impact factor: 3.315

2.  Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice.

Authors:  Adam E Mullick; Wuxia Fu; Mark J Graham; Richard G Lee; Donna Witchell; Thomas A Bell; Charles P Whipple; Rosanne M Crooke
Journal:  J Lipid Res       Date:  2011-02-22       Impact factor: 5.922

3.  Hepatocyte-specific, PPARγ-regulated mechanisms to promote steatosis in adult mice.

Authors:  Abigail Wolf Greenstein; Neena Majumdar; Peng Yang; Papasani V Subbaiah; Rhonda D Kineman; Jose Cordoba-Chacon
Journal:  J Endocrinol       Date:  2016-10-31       Impact factor: 4.286

4.  FoxO6 integrates insulin signaling with MTP for regulating VLDL production in the liver.

Authors:  Dae Hyun Kim; Ting Zhang; Sojin Lee; Virtu Calabuig-Navarro; Jun Yamauchi; Ann Piccirillo; Yong Fan; Radha Uppala; Eric Goetzman; H Henry Dong
Journal:  Endocrinology       Date:  2014-01-17       Impact factor: 4.736

5.  Hepatic Overexpression of CD36 Improves Glycogen Homeostasis and Attenuates High-Fat Diet-Induced Hepatic Steatosis and Insulin Resistance.

Authors:  Wojciech G Garbacz; Peipei Lu; Tricia M Miller; Samuel M Poloyac; Nicholas S Eyre; Graham Mayrhofer; Meishu Xu; Songrong Ren; Wen Xie
Journal:  Mol Cell Biol       Date:  2016-10-13       Impact factor: 4.272

6.  Nr4a1 is required for fasting-induced down-regulation of Pparγ2 in white adipose tissue.

Authors:  Kalina Duszka; Juliane G Bogner-Strauss; Hubert Hackl; Dietmar Rieder; Claudia Neuhold; Andreas Prokesch; Zlatko Trajanoski; Anne-M Krogsdam
Journal:  Mol Endocrinol       Date:  2012-12-18

7.  Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein.

Authors:  Richard G Lee; Wuxia Fu; Mark J Graham; Adam E Mullick; Donna Sipe; Danielle Gattis; Thomas A Bell; Sheri Booten; Rosanne M Crooke
Journal:  J Lipid Res       Date:  2012-12-06       Impact factor: 5.922

8.  Hepatic PPARγ Is Not Essential for the Rapid Development of Steatosis After Loss of Hepatic GH Signaling, in Adult Male Mice.

Authors:  Rhonda D Kineman; Neena Majumdar; Papasani V Subbaiah; Jose Cordoba-Chacon
Journal:  Endocrinology       Date:  2016-03-07       Impact factor: 4.736

9.  Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks.

Authors:  Sarah K Knutson; Brenda J Chyla; Joseph M Amann; Srividya Bhaskara; Stacey S Huppert; Scott W Hiebert
Journal:  EMBO J       Date:  2008-03-20       Impact factor: 11.598

10.  C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis.

Authors:  Amrom E Obstfeld; Eiji Sugaru; Marie Thearle; Anne-Marie Francisco; Constance Gayet; Henry N Ginsberg; Eleanore V Ables; Anthony W Ferrante
Journal:  Diabetes       Date:  2010-01-26       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.